Aurobindo Pharma Limited has incorporated a new wholly owned subsidiary, Engenra Biologics Private Limited, on February 24, 2026. The pharmaceutical company made this disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing both the National Stock Exchange of India Limited and BSE Limited about this corporate development.

Subsidiary Details and Capital Structure

Engenra Biologics Private Limited was incorporated in India as a newly formed entity in the pharmaceuticals industry. The subsidiary's financial structure and ownership details are outlined below:

Strategic Objectives and Business Purpose

The incorporation of Engenra Biologics Private Limited serves specific strategic purposes for Aurobindo Pharma's expansion plans. The primary objective is to expand contract manufacturing and other pharmaceutical manufacturing operations. This move aligns with the company's core business activities in the pharmaceuticals sector and represents a focused approach to enhancing manufacturing capabilities.

Regulatory and Compliance Aspects

The subsidiary formation involves several regulatory considerations and compliance requirements:

• Related Party Status: Engenra Biologics Private Limited is classified as a related party of Aurobindo Pharma due to its wholly owned subsidiary status
• Promoter Interest: The promoters and promoter group of Aurobindo Pharma have no separate interest in this transaction
• Regulatory Approvals: No governmental or regulatory approvals were required for this incorporation
• Completion Timeline: Not applicable as the incorporation has been completed

Company Background and Operations

As a newly incorporated entity, Engenra Biologics Private Limited has no operational history or previous turnover records. The company was established specifically on February 24, 2026, and will operate within India's pharmaceutical manufacturing landscape. The subsidiary will focus on contract manufacturing services and other pharmaceutical manufacturing operations, leveraging Aurobindo Pharma's existing expertise and market presence in the sector.

This strategic incorporation demonstrates Aurobindo Pharma's commitment to expanding its manufacturing capabilities and strengthening its position in the pharmaceutical contract manufacturing segment.

Aurobindo Pharma Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Dr. Punita Kumar Sinha as Independent Director. The notice, dated February 9, 2026, was communicated to stock exchanges under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Appointment Details

The company proposes to appoint Dr. Punita Kumar Sinha (DIN: 05229262) as Independent Director for a period of three consecutive years. The appointment term extends from February 9, 2026 to February 8, 2029, with the director not liable to retire by rotation.

Voting Schedule and Process

The postal ballot process follows a structured timeline with specific dates for member participation. Only electronic voting will be conducted, with no physical ballot forms being distributed to shareholders.

Members whose names appear on the Register of Members or List of Beneficial Owners as on February 20, 2026 are eligible to participate in the e-voting process. The company has engaged KFin Technologies Limited as the Registrar and Share Transfer Agent for facilitating the remote e-voting facility.

Director Profile and Qualifications

Dr. Punita Kumar Sinha brings extensive experience in capital markets and corporate governance. She is a seasoned global investor with over three decades of experience and formerly served as Senior Managing Director and CIO at Blackstone Asia Advisors, where she managed some of the largest India-focused funds globally.

Educational Qualifications:

• PhD and Master's in Finance from Wharton School, University of Pennsylvania
• Chemical Engineering degree from IIT Delhi
• CFA charterholder

Professional Experience:

• Currently serves as Independent Director on boards of several leading companies
• Has chaired key board committees including Audit, Nomination & Remuneration, Risk, CSR, and Stakeholders' Relationship Committees
• Brings deep expertise in ESG, investment management, and governance
• Recipient of Distinguished Alumni Award from IIT Delhi
• Recipient of Best Woman Director Award from Asian Centre for Corporate

Current Board Positions

Dr. Sinha currently holds directorships in multiple listed and unlisted companies, demonstrating her extensive governance experience across various sectors.

Listed Company Directorships:

• One Mobikwik Systems Limited
• Tata Capital Limited
• Aadhar Housing Finance Limited
• Ventive Hospitality Limited

Key Committee Roles:

• Serves as Chairperson of various committees including Nomination & Remuneration, Corporate Social Responsibility, and Stakeholders Relationship Committees
• Active member of Audit and Risk Management Committees across multiple organizations

Regulatory Compliance

The appointment follows all regulatory requirements under the Companies Act, 2013 and SEBI regulations. Dr. Sinha has provided necessary declarations confirming her independence criteria and eligibility for the position. The Board of Directors appointed MRR & Associates, Company Secretaries, represented by Mr. A. Mohan Rami Reddy as Scrutinizer for conducting the postal ballot process.

The company has confirmed that Dr. Sinha is not disqualified under Section 164(2) of the Companies Act and meets all independence criteria as specified under Section 149(6) of the Act and SEBI Listing Regulations. She has also confirmed compliance with the Independent Directors databank registration requirements maintained by the Indian Institute of Corporate Affairs.